Takeaway
- Patients with advanced-stage NSCLC rank shortness of breath, bleeding, and fatigue as the adverse effects of chemotherapy they would most like to avoid.
Why this matters
- Coupling patient preferences and profiles of commonly used chemotherapy regimens could result in patient-centered treatment plans with better outcomes.
Study design
- Researchers studied the treatment choices of patients with advanced-stage NSCLC (n=232; 55.6% men; 95.3% white) based on medical records and interviews.
- Funding: Patient-Centered Outcomes Research Institute.
Key results
- Before and after experiencing chemotherapy, patients selected the adverse effect they would most like to avoid:
- Shortness of breath (before, 28.7%; after, 20.8%);
- Unusual or increased bleeding (20.9%; 14.3%);
- Decreased energy or excessive fatigue (11.9%; 25.6%);
- Dizziness (10.8%; 10.7%);
- A lot more expensive (8.4%; 9.5%);
- Jaundice (8.4%; 7.7%);
- More trips to clinic for treatment (7.2%; 7.1%);
- Numbness or tingling (1.8%; 1.2%); and
- Brittle nails (1.8%; 2.9%).
Limitations
- Study data are not publicly available to protect patient confidentiality.
- Checkpoint inhibitors were not an approved first-line treatment during the study.
- Study results are limited to patients with advanced NSCLC.
Desafortunadamente este artículo no esta disponible para usuarios no logados
Has alcanzdo el límite de artículos por usuario
Acceso gratuito Un servicio exclusivo para profesionales sanitariosAcceder a
cuenta
¿No tienes cuenta? Comenzar